Diamyd Medical AB (publ) Total Assets
Diamyd Medical AB (publ) total assets. Based on the latest financial reports, Diamyd Medical AB (publ) (DMYD-B) holds total assets worth Skr406.63 Million SEK (≈ $43.76 Million USD) as of May 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see DMYD-B market cap for the company's overall valuation and market capitalisation.
Total Assets of Diamyd Medical AB (publ) (2010–2025)
Total assets of Diamyd Medical AB (publ) from 2010 to 2025. This chart illustrates how Diamyd Medical AB (publ)'s total assets have evolved over time, based on quarterly financial data. See Diamyd Medical AB (publ) (DMYD-B) share price today for real-time trading data and today's change.
Diamyd Medical AB (publ) - Asset Composition Analysis
Diamyd Medical AB (publ) Total Assets Breakdown (August 2025)
Diamyd Medical AB (publ) total assets breakdown as of August 2025. Diamyd Medical AB (publ)'s total assets of Skr406.63 Million consist of 82.9% current assets and 17.1% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr277.19 Million | 78.6% |
| Accounts Receivable | Skr4.09 Million | 1.2% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr52.70 Million | 15.0% |
| Intangible Assets | Skr0.00 | 0.0% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2010–2025)
This chart illustrates how Diamyd Medical AB (publ)'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Diamyd Medical AB (publ) (DMYD-B) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Diamyd Medical AB (publ)'s current assets represent 82.9% of total assets in 2025, a decrease from 91.5% in 2010.
- Cash Position: Cash and equivalents constituted 78.6% of total assets in 2025, down from 88.1% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2010.
- Asset Diversification: The largest asset category is cash and equivalents at 78.6% of total assets.
Diamyd Medical AB (publ) Competitors by Total Assets
Key competitors of Diamyd Medical AB (publ) based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Diamyd Medical AB (publ) - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 15.50 | 11.47 | 14.29 |
| Quick Ratio | 15.50 | 11.47 | 14.29 |
| Cash Ratio | 0.00 | 10.74 | 12.22 |
| Working Capital | Skr329.46 Million | Skr310.52 Million | Skr151.57 Million |
Diamyd Medical AB (publ) - Advanced Valuation Insights
This section examines the relationship between Diamyd Medical AB (publ)'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.60 |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | 62.5% |
| Total Assets | Skr352.64 Million |
| Market Capitalization | $16.14 Million USD |
Valuation Analysis
Below Book Valuation: The market values Diamyd Medical AB (publ)'s assets below their book value (0.05x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Diamyd Medical AB (publ)'s assets grew by 62.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Diamyd Medical AB (publ) (2010–2025)
The table below shows the annual total assets of Diamyd Medical AB (publ) from 2010 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-08-31 | Skr352.64 Million ≈ $37.95 Million |
+62.48% |
| 2024-08-31 | Skr217.04 Million ≈ $23.36 Million |
+5.46% |
| 2023-08-31 | Skr205.81 Million ≈ $22.15 Million |
-12.99% |
| 2022-08-31 | Skr236.52 Million ≈ $25.45 Million |
+17.42% |
| 2021-08-31 | Skr201.44 Million ≈ $21.68 Million |
+124.41% |
| 2020-08-31 | Skr89.76 Million ≈ $9.66 Million |
+20.97% |
| 2019-08-31 | Skr74.20 Million ≈ $7.99 Million |
+34.96% |
| 2018-08-31 | Skr54.98 Million ≈ $5.92 Million |
-44.26% |
| 2017-08-31 | Skr98.65 Million ≈ $10.62 Million |
+161.12% |
| 2016-08-31 | Skr37.78 Million ≈ $4.07 Million |
-19.01% |
| 2015-08-31 | Skr46.65 Million ≈ $5.02 Million |
-8.58% |
| 2014-08-31 | Skr51.02 Million ≈ $5.49 Million |
-24.76% |
| 2013-08-31 | Skr67.82 Million ≈ $7.30 Million |
-83.92% |
| 2012-08-31 | Skr421.74 Million ≈ $45.39 Million |
-18.83% |
| 2011-08-31 | Skr519.60 Million ≈ $55.92 Million |
-8.71% |
| 2010-08-31 | Skr569.19 Million ≈ $61.25 Million |
-- |
About Diamyd Medical AB (publ)
Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with ty… Read more